130 related articles for article (PubMed ID: 15389260)
21. Cytopathology of malignant mesothelioma: a stepwise logistic regression analysis.
Stevens MW; Leong AS; Fazzalari NL; Dowling KD; Henderson DW
Diagn Cytopathol; 1992; 8(4):333-41. PubMed ID: 1638933
[TBL] [Abstract][Full Text] [Related]
22. MMP-7 is a highly specific negative marker for benign and malignant mesothelial cells in serous effusions.
Davidson B; Stavnes HT; Hellesylt E; Hager T; Zeppa P; Pinamonti M; Wohlschlaeger J
Hum Pathol; 2016 Jan; 47(1):104-8. PubMed ID: 26520416
[TBL] [Abstract][Full Text] [Related]
23. Comparison of telomerase activity between malignant and tuberculous pleural effusions.
Maneechotesuwan K; Lertworawiwat A; Tscheikuna J; Wamanuttajinda V
J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S46-54. PubMed ID: 17718245
[TBL] [Abstract][Full Text] [Related]
24. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
Bassarova AV; Nesland JM; Davidson B
Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
[TBL] [Abstract][Full Text] [Related]
25. Expressions of human telomerase mRNA component (hTERC) and telomerase reverse transcriptase (hTERT) mRNA in effusion cytology.
Hiroi S; Nakanishi K; Kawai T
Diagn Cytopathol; 2003 Oct; 29(4):212-6. PubMed ID: 14506674
[TBL] [Abstract][Full Text] [Related]
26. Lower proliferation rate in metastatic effusion mesothelial cells than in benign effusions.
Rehnberg J; Zendehrokh N; Dejmek A
Anal Quant Cytol Histol; 2007 Aug; 29(4):217-20. PubMed ID: 17879629
[TBL] [Abstract][Full Text] [Related]
27. Small orangiophilic squamous-like cells: an underrecognized and useful morphological feature for the diagnosis of malignant mesothelioma in pleural effusion cytology.
Chen L; Caldero SG; Gmitro S; Smith ML; De Petris G; Zarka MA
Cancer Cytopathol; 2014 Jan; 122(1):70-5. PubMed ID: 23983174
[TBL] [Abstract][Full Text] [Related]
28. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
Hanley KZ; Facik MS; Bourne PA; Yang Q; Spaulding BO; Bonfiglio TA; Xu H
Cancer; 2008 Feb; 114(1):49-56. PubMed ID: 18098206
[TBL] [Abstract][Full Text] [Related]
29. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
[TBL] [Abstract][Full Text] [Related]
30. Monoclonal antibodies in the cytodiagnosis of serous effusions.
al-Nafussi A; Carder PJ
Cytopathology; 1990; 1(2):119-28. PubMed ID: 1714782
[TBL] [Abstract][Full Text] [Related]
31. Application of molecular genetics to the diagnosis of lymphoid-rich effusions: study of 95 cases with concomitant immunophenotyping.
Mihaescu A; Gebhard S; Chaubert P; Rochat MC; Braunschweig R; Bosman FT; Delacrétaz F; Benhattar J
Diagn Cytopathol; 2002 Aug; 27(2):90-5. PubMed ID: 12203875
[TBL] [Abstract][Full Text] [Related]
32. Cytomorphology, Immunophenotype, and cytogenetic profile of leukemic serous effusions.
Kaur K; Patel T; Patra S; Trivedi P
Diagn Cytopathol; 2021 Aug; 49(8):948-958. PubMed ID: 33973738
[TBL] [Abstract][Full Text] [Related]
33. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions.
Illei PB; Ladanyi M; Rusch VW; Zakowski MF
Cancer; 2003 Feb; 99(1):51-6. PubMed ID: 12589646
[TBL] [Abstract][Full Text] [Related]
34. Subclassification of lymphoproliferative disorders in serous effusions: a 10-year experience.
Tong LC; Ko HM; Saieg MA; Boerner S; Geddie WR; da Cunha Santos G
Cancer Cytopathol; 2013 May; 121(5):261-70. PubMed ID: 23460311
[TBL] [Abstract][Full Text] [Related]
35. Identification of adenocarcinoma in cytospin preparations of effusions using monoclonal antibody B72.3.
Martin SE; Moshiri S; Thor A; Vilasi V; Chu EW; Schlom J
Am J Clin Pathol; 1986 Jul; 86(1):10-8. PubMed ID: 3524191
[TBL] [Abstract][Full Text] [Related]
36. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
Su XY; Li GD; Liu WP; Xie B; Jiang YH
Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
[TBL] [Abstract][Full Text] [Related]
37. Weak telomerase activity in malignant cells in metastatic serous effusions: correlation to short survival time.
Zendehrokh N; Franzen L; Dejmek A
Acta Cytol; 2007; 51(3):412-6. PubMed ID: 17536544
[TBL] [Abstract][Full Text] [Related]
38. An improved flow cytometric assay for detection and discrimination between malignant cells and atypical mesothelial cells, in serous cavity effusions.
Kentrou NA; Tsagarakis NJ; Tzanetou K; Damala M; Papadimitriou KA; Skoumi D; Stratigaki A; Anagnostopoulos NI; Malamou-Lada E; Athanassiadou P; Paterakis G
Cytometry B Clin Cytom; 2011 Sep; 80(5):324-34. PubMed ID: 21695775
[TBL] [Abstract][Full Text] [Related]
39. [Differential diagnostic value of B72.3, Ber-EP4 and calretinin in serous effusions].
Li XJ; Pan QJ; Shen GH; Liu XY; Sun YT
Zhonghua Zhong Liu Za Zhi; 2005 Jul; 27(7):438-41. PubMed ID: 16188134
[TBL] [Abstract][Full Text] [Related]
40. Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies. Evaluation of five epithelial markers.
Davidson B; Risberg B; Kristensen G; Kvalheim G; Emilsen E; Bjåmer A; Berner A
Virchows Arch; 1999 Jul; 435(1):43-9. PubMed ID: 10431845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
